

1 High-speed imaging of glutamate release with genetically encoded sensors

2

3 Céline D. Dürst¹, J. Simon Wiegert^{1a}, Nordine Helassa^{2b}, Silke Kerruth^{2c}, Catherine Coates², Christian
4 Schulze¹, Michael Geeves³, Katalin Török² and Thomas G. Oertner^{1*}

5 ¹Institute for Synaptic Physiology, Center for Molecular Neurobiology Hamburg, Hamburg 20251, Germany

6 ²Molecular and Clinical Sciences Research Institute, St George's, University of London, London SW17 0RE, UK

7 ³School of Biosciences, University of Kent, Canterbury CT2 7NZ, UK

8 ^aPresent address: Research Group Synaptic Wiring and Information Processing, Center for Molecular Neurobiology
9 Hamburg, Hamburg 20251, Germany

10 ^bPresent address: Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University
11 of Liverpool, L69 3BX Liverpool, United Kingdom

12 ^cPresent address: Department of Biophysical Chemistry, J. Heyrovský Institute of Physical Chemistry, Dolejškova
13 2155/3, 182 00 Prague, Czech Republic

14 *corresponding author: thomas.oertner@zmnh.uni-hamburg.de

15

16 **KEYWORDS:** genetically-encoded glutamate indicator, GEGI, glutamate, two-photon imaging, two-
17 photon microscopy, synaptic transmission, stopped-flow, iGluSnFR, hippocampal culture, rat, pyramidal
18 cell, CA1, excitatory synapse, multivesicular release, organotypic culture, single-cell electroporation.

19 **EDITORIAL SUMMARY** This Protocol describes the design, *in vitro* characterisation and imaging
20 applications of iGluSnFR-based genetically-encoded glutamate indicators (GEGIs) in tissue culture of rat
21 hippocampus

22 **TWEET** A new protocol for the design, characterisation and high-speed imaging applications of
23 genetically-encoded glutamate indicators (GEGIs).

24 **COVER TEASER** High-speed imaging of glutamate release

25 **Up to three primary research articles where the protocol has been used and/or developed.**

26 **1.** Helassa, N. et al. Ultrafast glutamate sensors resolve high-frequency release at Schaffer collateral
27 synapses. Proc. Natl. Acad. Sci. U. S. A. 115, 5594–5599 (2018).

28 **2.**

29 **3.**

30

31 **Abstract**

32 The strength of an excitatory synapse depends on its ability to release glutamate and on the density of
33 postsynaptic receptors. Genetically-encoded glutamate indicators (GEGIs) allow eavesdropping on
34 synaptic transmission at the level of cleft glutamate to investigate properties of the release machinery in
35 detail. Based on the sensor iGluSnFR, we recently developed accelerated versions that allow
36 investigating synaptic release during 100 Hz trains. Here we describe the detailed procedures for design
37 and characterization of fast iGluSnFR variants *in vitro*, transfection of pyramidal cells in organotypic
38 hippocampal cultures, and imaging of evoked glutamate transients with two-photon laser scanning
39 microscopy. As the released glutamate spreads from a point source - the fusing vesicle - it is possible to
40 localize the vesicle fusion site with a precision exceeding the optical resolution of the microscope. By
41 using a spiral scan path, the temporal resolution can be increased to 1 kHz to capture the peak of fast
42 iGluSnFR transients. The typical time frame for these experiments is 30 min per synapse.

43 **Introduction**

44 One of the fundamental parameters setting synaptic strength is the release probability of the
45 presynaptic bouton. Release probability is classically assessed in electrophysiological recordings from the
46 postsynaptic neuron. In neocortex and hippocampus, however, two neurons are frequently connected
47 by more than one synapse, which makes it very difficult to achieve a situation where responses from a
48 single synapse can be electrophysiologically isolated. Furthermore, both presynaptic changes (vesicle
49 depletion, changes in release probability) and changes on the level of postsynaptic receptors (e.g.,
50 phosphorylation, desensitization, saturation, lateral diffusion, and internalization) contribute to the
51 variability of postsynaptic responses^{1,2}. These effects become even more difficult to disentangle during
52 high-frequency stimulation, when all physiological parameters change simultaneously as the synapse
53 struggles to maintain transmission. Due to these complications, it is an attractive proposition to assess
54 synaptic physiology with functional imaging methods, as they convincingly isolate responses from a
55 single synapse even if other synapses on the same neuron are active at the same time. While a large
56 number of imaging studies used postsynaptic Ca²⁺ transients as a read-out of synaptic efficacy, it is now
57 possible to intercept synaptic transmission at the level of cleft glutamate, effectively isolating
58 presynaptic dynamics from postsynaptic changes.

59 **Overview of optical glutamate sensors**

60 In the last decade, two types of optical glutamate sensors have been developed: chemically-labeled and
61 genetically-encoded glutamate indicators (GEGIs). Both types of sensors utilize a glutamate-binding
62 protein which is either labeled with a synthetic fluorophore or fused to a fluorescent protein. Sensors
63 based on the ligand-binding domain of AMPAR subunit conjugated with a small fluorescent dye molecule
64 near the glutamate-binding pocket have been used to image bulk extrasynaptic glutamate dynamics in
65 the brain^{3,4}. A chemical FRET-based approach, combining a donor and acceptor fluorophore with the
66 glutamate binding protein iGluR5-S1S2 (Snifit-iGluR5)⁵ showed an improved fluorescence change in
67 cultured cells but has not been applied to brain tissue yet. Sparse and cell-specific labeling without
68 background fluorescence, a precondition for single-synapse studies, seems to be difficult to achieve with
69 chemically labeled sensors.

70 The first fully genetically-encoded glutamate indicator (GEGI) called FLIPE⁶ was FRET-based and
71 contained a glutamate binding protein (GltI from *E.coli*) located between an N-terminal enhanced cyan
72 fluorescent protein (ECFP) and a C-terminal yellow fluorescent protein called Venus. Later improved to
73 reach a maximum CFP/YFP ratio change of 44% and a K_d of 2.5 μ M (Hires et al., 2008), the sensor named
74 SuperGluSnFR allowed measurements of the time course of synaptic glutamate release and spillover in
75 hippocampal cultures. However, the signal-to-noise ratio (SNR) of SuperGluSnFR was still low, and ~30
76 traces had to be averaged to measure glutamate release in response to single action potentials. A
77 significant improvement was the development of iGluSnFR⁹. iGluSnFR is an intensity-based glutamate
78 sensor constructed from *E. coli* GltI and circularly permuted (cp) EGFP. Its high fluorescence dynamic
79 range ($\Delta F/F_{max}$ of 4.5) and K_d of ~4 μ M make it a very suitable tool for investigating cleft glutamate
80 dynamics. iGluSnFR has been used to measure glutamate in a variety of tissues such as the retina¹⁰,
81 visual cortex¹¹ and olfactory bulb¹². We and others developed variants displaying different kinetics,
82 affinities and emission profiles¹³⁻¹⁵. Those new GEGIs with varied biophysical properties enable

83 researchers to select the most appropriate sensor depending on the biological question (bulk tissue vs.
84 single synapse) and imaging system (camera, galvanometric laser scanner, or resonant scanner).

85 **Comparison with other methods to image presynaptic function**

86 To image presynaptic function, fluorescent glutamate sensors are not the only possibility. The change in
87 vesicular pH during vesicle exocytosis and recycling/reacidification has been successfully exploited to
88 measure the activity of individual presynaptic terminals. Synapto-pHluorin, the first genetically-encoded
89 pH indicator, was based on a pH-sensitive GFP variant fused to the C-terminus of synaptobrevin/VAMP2
90 (vesicular associated membrane protein-2) to target the sensor to the inner surface of synaptic vesicles
91 ¹⁶. Other vesicular targeting strategies used fusion to synaptophysin ¹⁷, synaptotagmin ¹⁸ and the
92 vesicular glutamate transporter VGLUT ¹⁹. Spectrally red-shifted sensors with a red fluorescent pH-
93 sensitive protein like VGLUT-mOrange2 ²⁰ and sypHTomato ²¹ were developed, and the ratiometric
94 sensor Ratio-sypHy ²² was instrumental in revealing the arrested development of synapses in dissociated
95 neuronal culture. In addition, in primary cultures, pHluorins are sufficiently sensitive to detect single
96 vesicle release events ²³⁻²⁵. It is even possible to localize individual fusion events with a precision
97 exceeding the resolution limit of the microscope ²⁶. Analysis of release during high-frequency activity,
98 however, is difficult with pH-based methods: reuptake and reacidification are slow processes, leading to
99 rapid accumulation of green fluorescence inside active synaptic terminals. Furthermore, pH-based
100 indicators provide no information about the glutamate content (filling state) of individual vesicles.
101 Another technique to study presynaptic function is to image the loading and unloading of amphiphilic
102 styryl dyes (FM dyes), initially developed to study vesicle recycling at the neuromuscular junction (NMJ)
103 ²⁷. The lack of cellular selectivity prevents the use of FM dyes at individual synapses in the densely
104 packed neuropil. In addition, the relatively long partitioning time of FM dyes in- and out of the
105 membrane (seconds) renders the relation between staining/destaining events and sub-millisecond
106 glutamate release rather obscure.

107 **Overview of the Procedure**

108 The Procedure can be divided into two sections (see Fig. 1); sensor development (Steps 1-42) and
109 functional imaging of synaptic activity in hippocampal slice cultures (Steps 43-62).

110 **Sensor development (Steps 1-42):** While iGluSnFR is an excellent general-purpose GEGI, it may be
111 necessary to further optimize specific properties such as affinity for glutamate (K_d), brightness, or
112 kinetics for specific experiments. Optimization starts with structure-guided mutations of residues
113 close to the glutamate binding pocket (Fig. 1a) (Step 1). Newly generated variants are expressed in *E.*
114 *coli*, purified and tested *in vitro* for glutamate-induced changes in fluorescence (Steps 2-20). If the
115 dynamic range is deemed sufficient, affinity and kinetics are determined by stopped-flow fluorimetry
116 (Steps 21-37). The most promising candidates are expressed and characterized in HEK cells (Steps 38-
117 42) and finally, in neurons (Steps 43-62). We found considerable differences in the absolute affinity
118 and kinetics of sensor molecules in solution compared to the same molecules tethered to the plasma
119 membrane of cells ¹³. Relative differences between GEGIs, however, were conserved, validating the
120 use of *in vitro* calibrations for sensor optimization.

121 **Imaging synaptic function (Steps 43-62):** Single-cell electroporation is the method of choice to
122 achieve very sparse expression of glutamate sensors in organotypic culture of brain tissue (Fig. 1b)

123 (Steps 46-56). The sparse expression makes it easy to follow the axon of a patch-clamped sensor-
124 expressing neuron to a distal projection area, e.g., CA1. While camera-based systems are ideal for
125 functional imaging in dissociated neuronal culture, two-photon microscopy is typically used to detect
126 weak functional signals deep in scattering tissue (Steps 57-62). The optimal strategy for functional
127 imaging depends on the goal of the experiment: to obtain spatial information about the fusion sites
128 of vesicles on individual presynaptic boutons, we use fast frame scans and slower GEGIs (iGluSnFR)
129 (Step 62 Option A). To accurately determine the amplitude of individual glutamate transients, a
130 prerequisite for optical quantal analysis, spiral scans on individual boutons provide increased
131 temporal resolution and better signal-to-noise ratio (SNR) (Step 62 Option B). While 500 Hz provide
132 sufficient temporal resolution for iGluSnFR imaging, we increase the spiral scan frequency to 1 kHz
133 for ultrafast GEGIs.

134 **Limitations of the method**

135 Glutamate diffuses out of the synaptic cleft in less than 1 ms. Even the fastest GEGIs cannot monitor the
136 true kinetics of free glutamate diffusion as the sensor needs time to rearrange its conformation to
137 become fluorescent. In addition, scanning microscopy has limited temporal resolution. For capturing
138 sub-millisecond fluorescence changes, it would be necessary to park the excitation beam on the synaptic
139 cleft. This is not a technical problem, but in practice, point-scan experiments are extremely sensitive to
140 small lateral movements of the active bouton in the tissue. At the moment, galvanometric scanning can
141 still adequately sample the fastest GEGIs.

142 The number of trials that can be obtained from a single bouton is limited by the unavoidable bleaching of
143 the indicator molecules and eventual destruction of the release machinery by toxic photoproducts (e.g.,
144 oxygen radicals). Therefore, the laser exposition per single AP should be reduced to a minimum. To
145 measure GEGI transients in response to individual APs, we image in spiral mode for ~ 80 ms. We
146 routinely acquire ~ 100 trials from single boutons without any decay in amplitude or release probability
147 (see Experimental design and Supplemental Fig. 1c). By using lower laser power, this number can be
148 extended to 200 trials at the cost of a slightly lower SNR. Longer intervals between trials allow
149 replenishing indicator molecules by lateral diffusion, but this strategy is limited by the need for stable
150 whole-cell access during the entire experiment for reliable action potential generation.

151 **Experimental design**

152 **Development and characterization of fast glutamate probes:** Site-directed mutagenesis and protein
153 expression/purification are done following standard procedures and should lead to high yields of the
154 GEGIs with a purity $> 90\%$ in a single-step purification process (determined by SDS-PAGE). One of the
155 most important parameters is the fluorescence dynamic range ($F_{+glu} - F_{-glu} / F_{-glu}$) which is a measure of the
156 fluorescence change upon glutamate binding. If the dynamic range of the new GEGI variant is < 2 , the
157 probe's response to glutamate is not high enough to be suitable for cellular experiments.

158 The affinity of the GEGI, expressed as K_d , has to be appropriate for the expected glutamate concentration
159 in the cellular or tissue environment. If the goal of the experiment is to distinguish synaptic failures (no

160 glutamate release, no GEGI signal) from successes (stimulation-induced glutamate release), a very high
161 affinity is desirable. If a linear response is important, e.g., to estimate the number of vesicles released
162 simultaneously, a slightly lower affinity might be advantageous. For a GEGI to be a useful probe for *in*
163 *vivo* imaging, it also needs to be specific for glutamate. Therefore, binding to other ligands has to be
164 assessed (Fig. 2a). As iGluSnFR is based on the glutamate/aspartate ABC transporter protein (GltI), it is
165 expected that the sensor retains a significant affinity for aspartate. However, it should be unresponsive
166 to serine or glutamine. Most of the GEGIs indeed show a fluorescence response to aspartate binding,
167 sometimes even with higher fluorescence dynamic range than for glutamate. However, the affinity is
168 often lower, and fortunately, aspartate does not act as a neurotransmitter. Nevertheless, aspartate
169 sensitivity needs to be considered when monitoring glutamate in non-neuronal tissues or cellular
170 compartments.

171 To observe fast events like neurotransmission in synapses, the kinetics of the formation and decay of the
172 fluorescence state are critical. Thus, the association and dissociation of the purified GEGIs are
173 determined *in vitro* by stopped-flow fluorimetry (Fig. 2b). While performing association measurements,
174 it is essential to record baselines for the buffer to obtain the zero level of the PMT and for the glutamate-
175 free GEGI to obtain the starting point of the fluorescence increase. This recording is essential to detect
176 rapid phases ($>1000\text{ s}^{-1}$) that are faster than the resolution of the stopped-flow device (about 1 ms
177 mixing time) and thus appear as jumps. Recording the dissociation of glutamate from the GEGIs is
178 especially challenging, as the glutamate needs to be removed from the sensor, which is difficult due to
179 lack of chemical traps. We circumvent this obstacle by mixing the glutamate-bound GEGI with the high
180 affinity GluBP 600n (K_d about 600 nM)⁶. However, for low affinity variants, these measurements are
181 limited by the concentration of GluBP 600n available and by the very small decrease in fluorescence
182 amplitude. Low-affinity GEGIs ($K_d > 1\text{ mM}$) have to be saturated with glutamate concentrations in the
183 mM range, however, GluBP 600n is at best concentrated to be $\sim 1\text{ mM}$ in the optical cell. As only a small
184 fraction of the GEGI is dispossessed of its glutamate, only a very small decrease in fluorescence occurs
185 and, thus a small signal is observed.

186 For *in vivo* use of the GEGIs, the sensors need to be attached to the outer membrane of a cell. Thus, the
187 sensors are cloned in mammalian expression vectors, which add a mouse Ig κ -chain for secretion and a
188 PDGFR transmembrane helix for membrane attachment. In order to confirm correct localization, the
189 sensor is expressed in cell lines (HEK293T cells) and titrated with glutamate to determine the cellular K_d .
190 We found that the attachment to the outer membrane of the cell increases the variants' affinity for
191 glutamate by a factor of up to 20-fold. Relative differences between the variants, however, are
192 conserved¹³. This affinity increase needs to be considered when choosing a suitable sensor for *in vivo*
193 applications.

194 **Imaging synaptic glutamate release with two-photon microscopy:** For expression in neurons, we clone
195 the GEGIs behind the human synapsin 1 promoter and electroporate single neurons in organotypic slice
196 cultures of rat hippocampus. GEGIs are relatively dim in the absence of glutamate, making it difficult to
197 focus on small structures such as axonal boutons. We routinely use co-expression of a bright red
198 fluorescent protein (tdimer2 or tdTomato) to label the cytoplasm and follow the axon through the tissue;
199 the newly developed CyRFP1²⁸ is also an excellent choice for this purpose. The red fluorescence also

200 provides additional information about the volume of individual boutons. Electroporated CA3 neurons are
201 clearly visible under a stereomicroscope (5x objective, DsRed filter set) 2-4 days after electroporation
202 (Fig. 3a-c). Two-photon excitation at 980 nm reveals axons and boutons of the expressing neurons in CA1
203 *stratum radiatum*, far away from the somata in CA3 (Fig. 3c). Targeted patch-clamp recording from a
204 transfected neuron allows triggering single action potentials (APs) by brief depolarizing current injections
205 (Fig. 3e). Simultaneous imaging of a single bouton (spiral scan path at high zoom (Fig. 5a-c)) reveals green
206 fluorescence transients time-locked to the action potentials, indicating glutamate release from the
207 stimulated bouton. In spite of reliable action potential generation, synapses frequently failed to release
208 glutamate (Fig. 3e, gray traces), indicating a stochastic vesicle fusion process.

209 **Fusion site localization:** While spiral scans are optimal to determine the peak amplitude of the
210 glutamate signal, we use fast frame scans (16 x 16 pixels, frame rate 62.5 Hz) to localize the likely
211 location of the fusing vesicle in individual trials. The spatial peak of the averaged signal does not
212 necessarily occur in the center of the bouton, but often close to the edge (Fig. 4b), reflecting the random
213 orientation of the synaptic cleft on the surface of the bouton. To localize individual fusion events in noisy
214 images, we fit a two-dimensional Gaussian kernel (Fig. 4c) to the first frame after stimulation. Plotting
215 the center positions of Gaussian fits (Fig. 4c) relative to the morphological outline of the bouton (red
216 channel) revealed a small region of release, the active zone (Fig. 4d). Increasing the extracellular Ca^{2+}
217 concentration from 1 mM to 4 mM did increase the amplitude of single-trial responses, but not the size
218 of the apparent active zone (Fig. 4e). The higher cleft glutamate concentrations caused by single action
219 potentials in 4 mM Ca^{2+} suggest the simultaneous release of multiple vesicles or a switch from partial to
220 full release. No clustering was found when we fitted green fluorescence before stimulation or in trials
221 classified as failures (Fig. 4f and g).

222 **Spiral scans and amplitude extraction:** As we do not know a priori where on the bouton the highly
223 localized and short-lived GEGI signals will appear (Fig. 5a), we need to sample the entire surface of the
224 bouton as fast as possible. Traditional raster scanning (Fig. 5b) requires extreme acceleration of the
225 scanning mirror at the end of every scan line, limiting the maximum frame rate to ~ 120 Hz. By scanning a
226 spiral pattern, we are able to sample the same area at frequencies up to 1 kHz. The point spread function
227 (PSF) of our two-photon microscope is $0.5 \mu\text{m}$ in the imaging plane and $1.7 \mu\text{m}$ along the optical axis
228 (FWHM, measured with 170 nm fluorescent beads). As the PSF is elongated in the axial direction, we
229 sample the upper and lower surface of the bouton simultaneously. Our goal is to extract the amplitude
230 of fluorescent transients from spiral scans independent of the exact position of the fusion site on the
231 bouton. To do so, the unfolded spiral scans are plotted as straight lines underneath each other, resulting
232 in a space-time plot (Fig. 5c). Typically, the spiral scan intersects the diffusing cloud of glutamate two or
233 three times per scan, resulting in multiple 'hot spots' that all contained information about the same
234 release event. To extract amplitude information, columns (corresponding to positions on the bouton) are
235 sorted according to the change in fluorescence (Fig. 5d). The columns with the largest signal ($\Delta F >$
236 $\Delta F_{\text{max}}/2$) are averaged (region of interest, ROI). In trials where no fluorescence change is detected
237 (failures), the same columns as in the last 'success' trial are analyzed. As opposed to a static region-of-
238 interest (ROI), this analysis procedure is robust against minute drift of the tissue between trials and does
239 not require a priori knowledge of the fusion location. We extract the amplitude from the resulting
240 fluorescence trace by fitting a single exponential function to the decay of the fluorescence transient. To

241 estimate the noise level (photon shot noise) in every experiment, we perform the same fitting procedure
242 to a section of the baseline (before stimulation). As expected, the baseline amplitudes are close to zero
243 (Fig. 5f, gray dots and columns). Typically, the histogram of all responses (green) also show one cluster
244 around zero (failures of release), the remaining responses (successes) form an asymmetric, broad peak
245 between 40 and 160% $\Delta F/F_0$. A close inspection of the spatial distribution of the signal (Fig. 5e, average
246 of 10 successes) shows a rapid decay of the peak, but no lateral spread as might be expected from a
247 diffusion process. It is important to note that the diffusion of free glutamate out of the synaptic cleft
248 happens in less than 1 ms and cannot be resolved by iGluSnFR or another GEGI. Instead, what we
249 observe is the relatively slow unbinding of glutamate from quasi-stationary iGluSnFR molecules,
250 explaining the lack of lateral spread of the signal.
251

252 **Materials**

253 **Reagents**

- 254 • Plasmids
 - 255 ○ pCMV iGluSnFR (Addgene plasmid #41732)⁹, iGluSnFR in mammalian expression vector,
256 can be used for expression in HEK293T cells and as starting point for SDM to induce new
257 mutations
 - 258 ○ pET41a(+) (Novagen, Merck cat. no. 70556-3), bacterial expression vector used to
259 express GEGI variants in *E. coli*
 - 260 ○ pET30b (Merck cat. no. 69909), bacterial expression vector used to express GEGI variants
261 in *E. coli*
 - 262 ○ pCI syn iGluSnFR (Addgene plasmid #106123), mammalian expression vector to express
263 iGluSnFR in neurons (hippocampal slices)
 - 264 ○ pDisplay FLIPE-600n (Addgene plasmid # 13545)⁶, vector encoding for GluBP 600n for
265 expression of glutamate-binding protein GluBP 600n in *E. coli*. Purified GluBP is used for
266 kinetic analysis *in vitro*.
 - 267 ○ pCI syn iGlu_f (Addgene plasmid #106121)¹³, mammalian expression vector for expression
268 of iGlu_f in neurons
 - 269 ○ pCI syn iGlu_u (Addgene plasmid #106122)¹³, mammalian expression vector for expression
270 of iGlu_u in neurons
 - 271 ○ pCI syn tdimer2, a gift of Roger Y. Tsien²⁹, mammalian expression vector for expression
272 of dimeric red fluorescent protein in neurons
- 273 • Cloning and molecular biology
 - 274 ○ Restriction enzymes: BglII, NotI (NEB cat. no. R0144 and R0189)
 - 275 ○ T4 DNA ligase (NEB cat. no. M0202)
 - 276 ○ QuikChange XL Site-Directed Mutagenesis Kit (Agilent Technologies cat. no. 200516)
 - 277 ○ NucleoSpin[®] Plasmid kit (Machery and Nagel cat. no. 740588)
 - 278 ○ HiSpeed Plasmid Midi Kit (Qiagen cat. no. 12643)
 - 279 ○ LB Broth (Powder) - Lennox (Fisher BioReagents cat no. BP1427)
 - 280 ○ LB Agar, Lennox (Granulated) (Fisher BioReagents cat no. BP9745)
 - 281 ○ Kanamycin sulfate (Fisher BioReagents cat no. BP906)

- 282 **CAUTION:** toxic. Wear protective gloves, clothing, and eye protection. Wash hands
283 thoroughly after handling.
- 284 ○ PureLink HiPure Plasmid Maxiprep (Life Technologies cat. no. K210006)
- 285 ● General reagents
- 286 ○ HEPES (Fine White Crystals/Molecular Biology) (Fisher Scientific cat. no. BP310-1)
- 287 ○ Sodium chloride, BioXtra, ≥99.5% (AT) (Merck cat. no. S7653)
- 288 ○ 1 M MgCl₂ solution (Invitrogen AM9530G)
- 289 ○ Sodium hydroxide (Merck cat no. S8045)
- 290 **CAUTION:** Danger. Corrosive to metals and causes severe skin burns and eye damage.
291 Wear protective gloves, clothing, and eye protection. Wash hands thoroughly after
292 handling.
- 293 ○ D(+)-Glucose (Merck cat no. D9434)
- 294 ○ Potassium chloride, BioXtra, ≥99.0% (Merck cat no. P9333)
- 295 ○ NaH₂PO₄ (Merck cat no. S0751)
- 296 ● Protein expression and purification
- 297 ○ Pierce™ Protease Inhibitor Tablets, EDTA-free (Thermo Fisher Scientific cat. no. A32965)
- 298 **CAUTION:** Danger, causes severe skin burn and eye damage. Wear protective gloves,
299 clothing and eye protection. Wash hands thoroughly after handling.
- 300 **CRITICAL:** EDTA-free inhibitor is critical to ensure binding of the His tagged protein to the
301 HisTrap High Performance column
- 302 ○ HisTrap™ High Performance (GE Healthcare cat. no. 17524801)
- 303 ○ SnakeSkin™ Dialysis Tubing, 3.5K MWCO, 22 mm (Thermo Fisher Scientific cat. no.
304 68035)
- 305 ● Glutamate, aspartate, and serine titration
- 306 ○ L-Glutamic acid (Merck cat. no. G1251)
- 307 ○ L-Aspartic acid (Merck cat. no. A8949)
- 308 ○ L-Serine (Merck cat. no. S4500)
- 309 ● Testing in cell lines
- 310 ○ HEK293T cells (Merck cat. no. 85120602)
- 311 **CAUTION:** The cell lines used in your research should be regularly checked to ensure
312 they are authentic and are not infected with mycoplasma.
- 313 ○ Sensorplate, 24 well, PS, F-bottom, glass bottom, black, lid, sterile, single packed
314 (Greiner bio one cat. no. 662892)
- 315 ○ DMEM, high glucose, GlutaMAX™ Supplement, pyruvate (Gibco, Thermo Fisher Scientific
316 cat. no. 31966047)
- 317 ○ MEM Non-Essential Amino Acids Solution (100X) (Gibco, Thermo Fisher Scientific cat. no.
318 11140035)
- 319 ○ Fetal Bovine Serum (FBS), qualified, heat inactivated, E.U.-approved, South America
320 Origin (Gibco, Thermo Fisher Scientific cat. no. 10500056)
- 321 ○ Penicillin-Streptomycin (10,000 U/mL) (Gibco, Thermo Fisher Scientific cat. no.
322 15140122)

- 323 **CAUTION:** Causes skin irritation, eye irritation, may cause an allergic skin reaction and
324 respiratory irritation. Wear protective gloves, clothing, and eye protection. Wash hands
325 thoroughly after handling.
- 326 ○ Lipofectamine™ 2000 Transfection Reagent (Thermo Fisher Scientific cat. no. 11668027)
- 327 ● Slice culture and recording
- 328 ○ Slice cultures from rodent hippocampus³⁰
- 329 **CAUTION:** Any experiments involving live rats must conform to relevant Institutional and
330 National regulations. In our case, organ explant procedures were approved by the
331 veterinary of the University Medical Center Hamburg-Eppendorf, Germany
- 332 ○ MEM (Sigma-Aldrich cat. no. M7278)
- 333 ○ Heat-inactivated horse serum (Gibco cat. no. 16050-122)
- 334 ○ L-glutamine (200 mM; Gibco cat. no. 25030-024)
- 335 ○ L-ascorbic acid (Sigma-Aldrich, cat. no. A5960)
- 336 ○ Insulin (1 mg/mL; Sigma-Aldrich cat. no. I1882)
- 337 ○ HEPES (Sigma-Aldrich cat. no. H4034)
- 338 ○ K-gluconate (Sigma-Aldrich, cat. no. G4500)
- 339 ○ EGTA (Sigma-Aldrich, cat. no. E0396)
- 340 ○ Na₂-ATP (Sigma-Aldrich, cat. no. A3377)
- 341 ○ Na-GTP (Sigma-Aldrich, cat. no. G8877)
- 342 ○ Na₂-phosphocreatine (Sigma-Aldrich, cat. no. P7936)
- 343 ○ NaHCO₃ (Sigma-Aldrich, cat. no. S5761)
- 344 ○ NaH₂PO₄ (Sigma-Aldrich, cat. no. S5011)
- 345 ○ Potassium chloride (Sigma-Aldrich, cat. no. S5886)
- 346 ○ 1 M KCl (Fluka cat. no. 60121)
- 347 ○ 1 M MgSO₄ (Fluka cat. no. 63126)
- 348 ○ 1 M MgCl₂ (Fluka, cat. no. 63020)
- 349 ○ 1 M CaCl₂ (Fluka cat. no. 21114)
- 350 ○ D-glucose (Fluka cat. no. 49152)
- 351 ○ Cl₃Fe (Fluka cat. no. 10695862)

352 **Reagent Setup**

353 **Resuspension buffer for expression:** 50 mM HEPES-Na⁺, 200 mM NaCl, pH 7.5, filtered (0.2 μm
354 pore size) and stored at 4°C for 2 weeks

355 **Elution buffer for expression:** 50 mM HEPES-Na⁺, 200 mM NaCl, 500 mM imidazole, pH 7.5,
356 filtered (0.2 μm pore size) and stored at 4°C for 2 weeks

357 **Storage buffer for expression:** 50 mM HEPES-Na⁺, 100 mM NaCl, pH 7.5, stored at 4°C for 2
358 weeks

359 **Assay buffer for biophysical characterization:** 50 mM HEPES-Na⁺, 100 mM NaCl, 2 mM MgCl₂,
360 pH 7.5, stored at 4°C for 2 weeks

361 **Association buffers for biophysical characterization:**

- 362 • 1 μ M GEGI in assay buffer, stored at 4°C for one day.
363 • 0.1x K_d to 10x K_d glutamate in assay buffer, stored at 4°C for one day
364 **CRITICAL:** In order to measure the full range of response in dependence of the glutamate
365 concentration, the glutamate concentration mixed with the GEGI has to be distributed around
366 the K_d

367 **Dissociation buffers for biophysical characterization:**

- 368 • 2 mM GluBP 600n in assay buffer, stored at 4°C for one day.
369 • 1 μ M GEGI in assay buffer, stored at 4°C for one day.
370 • 1 μ M GEGI in assay buffer with saturating glutamate (10x K_d), stored at 4°C for one day

371 **Complete DMEM:** DMEM, 1x NEAA, 10% (v/v) FBS, 100 U/ml penicillin-streptomycin, stored at
372 4°C for 2 month.

373 **HEK293T cell imaging buffer:** 20 mM HEPES- Na^+ , 145 mM NaCl, 10 mM glucose, 5 mM KCl, 1 mM
374 MgCl_2 , 1 mM NaH_2PO_4 , pH 7.4 stored at 4°C for up to 6 month.

375 **Slice culture medium:** 394 ml MEM, 20% (v/v) Heat-inactivated horse serum, 1 mM L-glutamine,
376 0.01 mg/ml Insulin, 14.5 mM NaCl, 2 mM MgSO_4 , 1.44 mM CaCl_2 , 0.00125% Ascorbic acid, 13 mM
377 D-glucose. Medium has to be sterile filtered (0.2 μ m pore size) and stored at 4°C for up to 4
378 weeks.

379 **Slice culture transduction solution:** 10 mM HEPES, 145 mM NaCl, 25 mM D-glucose, 2.5 mM KCl,
380 1 mM MgCl_2 , 2 mM CaCl_2 . Measure the pH using a pH-meter and adjust to pH 7.4 by adding
381 NaOH or HCl. Measure the osmolality with a micro-osmometer and ensure that the osmolality is
382 between 310-320 mOsm/kg. If the osmolality is out of range, a mistake was made during
383 solution preparation. Solution has to be sterile filtered (0.2 μ m pore size), stored at 4°C for up to
384 6 months and pre-warmed to 37°C before use.

385 **Recording solution, artificial cerebrospinal fluid (ACSF):** 25 mM NaHCO_3 , 1.25 mM NaH_2PO_4 , 127
386 mM NaCl, 25 mM D-glucose, 2.5 mM KCl, 2 mM CaCl_2 , 1 mM MgCl_2 , pH adjusted to 7.4, ACSF has
387 to be saturated with 95% O_2 and 5% CO_2 . Osmolality should be between 310-320 mOsm/kg.
388 Store for max. 1 week at 4°C. Bubble with Carbogen (95% O_2 , 5% CO_2) during warm-up to
389 prevent Ca^{2+} precipitation. Maintain perfusion reservoir at 34°C to prevent bubble formation in
390 recording chamber.

391 **K-gluconate-based intracellular solution:** 10 mM HEPES, 135 mM K-gluconate, 0.2 mM EGTA, 4
392 mM MgCl_2 , 4 mM $\text{Na}_2\text{-ATP}$, 0.4 mM Na-GTP , 10 mM $\text{Na}_2\text{-phosphocreatine}$, 3 mM L-ascorbic acid,
393 pH adjusted to 7.2 with KOH. Osmolality should be between 290-300 mOsm/kg. Solution has to
394 be sterile filtered (0.2 μ m pore size), stored at -20°C. Aliquot in Eppendorf tubes can be stored at
395 -80°C for max. 6 months. Store on ice during the experiment to slow down ATP hydrolysis.

396 **Equipment**

- 397 • Equipment for protein expression/purification

- 398 ○ Sonicator for lysing *E. coli* (Sonics & Materials Inc., VibraCell)
- 399 ○ ÄKTA Purifier or Explorer (GE healthcare)
- 400 • Equipment for biophysical characterization
- 401 ○ Fluorescence spectrometer with magnetic stirring function (Fluorolog3, Horiba Scientific)
- 402 ○ Hellma® fluorescence cuvettes, ultra Micro (Merck, cat. no. Z802336-1EA)
- 403 ○ Hellma fluorescence cuvette QS 3500 µL (Merck, cat. no. Z600172-1EA)
- 404 ○ ALADDIN syringe pump (World Precision Instruments, cat. no. AL-1000)
- 405 ○ SGE syringe 250 µL, barrel inner diameter 2.30 mm (Trajan Scientific and Medical, cat. no. P/N 006230)
- 406
- 407 ○ 'KinetAsyst' Dual-mixing Stopped-Flow System (TgK Scientific, cat. no. SF-61DX2)
- 408 equipped with two circulating water baths for temperature control and a long-pass filter
- 409 >530 nm. The equipment should be set up in a dark lab with red light illumination and
- 410 temperature control (20°C)
- 411 • Equipment for imaging in cell lines
- 412 ○ Inverted spinning-disk confocal fluorescence microscope (3i Marianas)
- 413 • Electrophysiology equipment
- 414 ○ pE-4000 LED light source (CoolLED) for epifluorescence
- 415 ○ infrared Dodt contrast (Luigs & Neumann)
- 416 ○ Patch-clamp amplifier (Axon Instruments, model no. MultiClamp 700B)
- 417 ○ Microelectrode manipulator (Sutter Instrument, MP-285).
- 418 ○ Micropipettes for whole-cell recording (Borosilicate glass with filament, 1.5 mm O.D.)
- 419 • Electroporation equipment
- 420 ○ Upright microscope with a motorized stage, CCD camera and IR-DIC (infrared differential
- 421 interference contrast) or Dodt contrast
- 422 ○ 20x water immersion objective (Zeiss Achroplan)
- 423 ○ 4x zoom lens system (0.5 – 2.0x magnification range)
- 424 ○ Vibration isolation table (Table Stable LTD, TS-150)
- 425 ○ Axoprotor 800A with HL-U pipette holder (Molecular Devices)
- 426 ○ Plastic syringe body (1 ml) as disposable mouthpiece, connected through a Luer 1-way
- 427 stopcock and thin silicone tubing to the electrode holder
- 428 ○ Headphones and speakers
- 429 ○ Microscope chamber made of a glass microscope slide (70 x 100 x 1 mm) onto which a
- 430 Teflon ring (inner diameter: ~ 35 mm, height: 2 mm) is fixed with silicone aquarium
- 431 sealant
- 432 ○ Motorized micromanipulators (Luigs & Neumann)
- 433 ○ Silver wire (diameter: ~ 0.25 mm)
- 434 ○ Forceps (Fine Science Tools, cat. no. 11002-16)
- 435 ○ Hot bead sterilizer (Fine Science Tools, cat. no. 18000-45)
- 436 ○ Incubator (37°C; 5% CO₂) with rapid humidity recovery and copper chamber (Heracell
- 437 150i/160i, Thermo Scientific)
- 438 ○ Micropipette puller (PC-10, Narishige)
- 439 ○ Thin-walled borosilicate glass capillaries (WPI, cat. no. TW150F-3)

- 440 ○ Tissue culture dishes (60 mm, sterile; Sarstedt, cat. no. 83.1801)
- 441 ○ Ultrafree centrifugal filter units (Millipore, cat. no.UFC30GV0S)
- 442 ○ Micro-osmometer (Fiske Model 210)
- 443 **CRITICAL:** The electroporation microscope should be situated close to the tissue culture
- 444 hood (in the same room) to prevent contamination. We built a laminar flow cabinet with
- 445 HEPA filter unit around the electroporation setup. The microscope has to be
- 446 mechanically isolated from the vibrations generated by the fan in the filter box; we use
- 447 an active anti-vibration table.
- 448 ● Software
 - 449 ○ ImageJ2 (<https://imagej.net/ImageJ2>)
 - 450 ○ GraphPad Prism 7 (<https://www.graphpad.com/>)
 - 451 ○ ScanImage 3.8 ³¹ (<https://vidriotechnologies.com/>)
 - 452 ○ Ephus ³² (<https://www.janelia.org/open-science/ephus>)

453 **Equipment Setup**

- 454 ○ **Equipment for functional imaging in tissue:** We built a two-photon microscope based on
- 455 an Olympus BX51WI microscope with pE-4000 LED light source (CoolLED) for
- 456 epifluorescence and infrared Dodt contrast (Luigs & Neumann). A Ti:Sapphire laser
- 457 system with dispersion compensation (MaiTai DeepSee, Spectra Physics) was coupled in
- 458 through an electro-optical modulator (EOM, Conoptics), a 3x telescope (Thorlabs), 5 mm
- 459 scan mirrors (Cambridge), a compound scan lens ($f = 50 \text{ mm}^{33}$), a dual camera port with
- 460 IR mirror (Olympus) and a water immersion objective (LUMPLFLN 60XW, 60x, NA 1.0,
- 461 Olympus). Red and green fluorescence was detected through the objective and the oil
- 462 immersion condenser (NA 1.4, Olympus) using 2 pairs of photomultiplier tubes (H7422P-
- 463 40SEL, Hamamatsu). 560 DXCR dichroic mirrors and 525/50 and 607/70 emission filters
- 464 (Chroma Technology) were used to separate green and red fluorescence. Excitation light
- 465 was blocked by short-pass filters (ET700SP-2P, Chroma). During epifluorescence
- 466 illumination, sub-stage PMTs were protected by a NS45B shutter (Uniblitz). For electrical
- 467 stimulation of individual neurons, we mounted the head-stage of a MultiClamp 700B
- 468 amplifier (Molecular Devices) on a MP-285 micromanipulator (Sutter Instruments) on a
- 469 motorized stage (40-40, Danaher Motion) that also moved the perfusion chamber
- 470 (quartz glass bottom). Temperature was controlled by Peltier-heating of the oil-
- 471 immersion condenser and in-line heating of the perfusion solution (Warner Instruments).
- 472 The setup was controlled by Matlab software (ScanImage ³¹ and Ephus ³²) via data
- 473 acquisition boards (National Instruments). At the start of a trial, electrophysiology and
- 474 image acquisition were synchronized by a hardware trigger (TTL pulse). During a trial (2 s,
- 475 typically), laser power was regulated via EOM and restricted to the periods of expected
- 476 glutamate release (20 - 80 ms window, depending on GEGl kinetics) to minimize
- 477 bleaching.

478 **CRITICAL:** To minimize bleaching by excessive excitation, the microscope has to be

479 designed to detect emitted photons very efficiently. Using only the objective for

480 fluorescence detection is not sufficient to achieve single-vesicle sensitivity. Condenser
481 detection (oil-immersion, 1.4 NA, large field of view) is essential for the success of single
482 synapse experiments with many trials. Replace aging PMTs with excessive dark counts.

483 **CRITICAL:** The oil-immersion condenser has to be permanently heated (day and night) if
484 a recording temperature above room temperature is desired. This can be achieved with
485 flexible heating pads or Peltier elements. As the thermal mass of the condenser is very
486 large, constant-current heating is sufficient, provided that the temperature of the
487 perfusion solution is additionally regulated by a feedback control circuit (in-line heater,
488 Warner Instruments). A climate chamber would be an attractive solution but is not
489 compatible with direct-mounted PMTs.

490 **CRITICAL:** If a galvanometric scanning system is used, the microscope software has to
491 support arbitrary line scans or spiral scans³⁴. The code for arbitrary line scans that we
492 developed for our original study is now incorporated in the ScanImage software (Version
493 2016 and later). ScanImage is developed and supported by Vidrio Technologies, LLC as an
494 open-source research resource. A resonant scanning system may be sufficiently fast in
495 frame mode if extreme zoom-in (few scan lines) can be realized.

496 Procedure

497 Generation of GEGIs **Timing 1 week (5 h hands-on time)**

498 **CRITICAL:** We have made a number of GEGI-encoding plasmids available via Addgene (see Reagents).
499 Follow Steps 1-42 in order to design GEGIs with tailored biophysical parameters.

- 500 1. Analyze protein 3D structures of the 99% homolog of GlI1 of *Shigella flexneri* (PDB 2VHA) and
501 literature^{35,36} to assign critical residues involved in glutamate binding. Substitute essential
502 residues with amino acids with similar physical properties. Avoid radical changes in amino acid
503 size or charge as this will frequently result in misfolded or otherwise non-functional proteins.
- 504 2. Subclone the iGluSnFR gene from a mammalian expression vector into a bacterial expression
505 vector (pET41a) using restriction digestion of BgIII and NotI and ligation (T4 DNA ligase) following
506 the manufacturer's protocol.
507 **CAUTION:** Subcloning requires DNA to be analyzed by agarose gels. This requires the use of DNA
508 intercalating fluorescent dyes (e.g. ethidium bromide or Sybr green) which highly toxic as
509 mutagens and should be handled with care. DNA imaging systems are based on UV lamps so
510 appropriate personal protective equipment should be used.
- 511 3. Insert point mutations using the QuikChange XL site-directed mutagenesis kit following the
512 manufacturer's instructions and confirm new variants by DNA sequencing.
- 513 4. Subclone *glti* gene encoding GluBP 600n from pRSET FLIPE 600n (ECFP-ybeJ-Venus) into pET30b
514 (His-fusion expression vector) at BgIII and NotI restriction sites.

515 Expression and purification of new GEGIs **Timing 3 days (10 h hands-on time)**

- 516 5. Transform 1 μL of iGluSnFR variants or GluBP 600n plasmid DNA into 50 μL of *E. coli* BL21 (DE3)
 517 gold chemically competent cells.
- 518 6. Pick one colony and grow in 10 mL LB-medium supplemented with 100 $\mu\text{g}/\text{mL}$ kanamycin for
 519 overnight at 37°C and 180 rpm (pre-culture).
- 520 7. Inoculate 1 L LB-medium containing 100 $\mu\text{g}/\text{mL}$ kanamycin with whole pre-culture, incubate at
 521 37°C and 180 rpm until OD_{600} reaches (0.6-0.8).
- 522 8. Cool the cells down to 20°C.
- 523 9. Induce protein expression with 0.5 mM Isopropyl β -D-1-thiogalactopyranoside (IPTG) and
 524 incubate at 20°C and 180 rpm overnight.
- 525 **CRITICAL STEP:** Best protein yields are obtained when inducing expression during exponential
 526 phase of growth (OD_{600} 0.6-0.8), overnight at 18-20 °C.
- 527 10. Harvest cells by centrifugation at 3000 *g* for 15 min at room temperature, resuspend cells in
 528 40 mL resuspension buffer supplemented with Pierce Protease Inhibitors and lyse via sonication
 529 on ice for 2 min (2 sec “on” and 8 sec “off”).
- 530 **CAUTION:** Wear ear protection equipment during sonication.
- 531 **CRITICAL STEP:** Sonication produces heat and may result in the degradation of your protein of
 532 interest. Performing sonication on ice and in the presence of protease inhibitors will dramatically
 533 limit this phenomenon.
- 534 11. Remove the cell debris by ultracentrifugation at 100,000 *g* for 45 min at 4°C.
- 535 **CRITICAL STEP:** After cell lysis, all steps are performed at 4°C when possible to avoid protein
 536 digestion by cellular proteases (steps 12-14).
- 537 12. Load the supernatant on equilibrated HisTrap HP column (nickel affinity resin) mounted on an
 538 ÄKTA system (flow rate 4 mL/min) and wash with 40 mL resuspension buffer.
- 539 13. Elute the protein with 10 column volumes of a linear gradient of resuspension and elution buffer
 540 (0 to 0.5 M imidazole) and collect in 2 mL fractions. Analyze the purified protein by SDS-PAGE
 541 and stain the gel with Coomassie blue.
- 542 14. Pool fractions of interest and dialyze overnight at 4°C in a snakeskin dialysis tubing (3.5 kDa)
 543 against 4 L storage buffer.
- 544 **CRITICAL STEP:** It is essential to perform dialysis to remove the imidazole from your buffer.
 545 Otherwise, protein precipitation will occur upon defrosting (from step 15). The dialysis
 546 molecular weight cut-off used can be higher than 3.5 kDa as long as it is below 15 kDa.
- 547 15. Store purified protein in fractions of 1 mL in the -80°C freezer.
- 548 **PAUSE POINT:** The purified protein can be stored at -80°C for up to 3 years.

549 **Determining the dynamic range** **Timing 1 h**

- 550 16. Prepare 50-100 nM iGluSnFR proteins in assay buffer, add to a Hellma micro cuvette (50 μL) and
 551 place the cuvette into a fluorescence spectrometer pre-equilibrated to 20 °C.
- 552 17. Record the fluorescence emission spectrum ($\lambda_{\text{ex}} = 492 \text{ nm}$ and $\lambda_{\text{em}} = 497\text{-}550 \text{ nm}$) ($F_{\text{-glu}}$).
- 553 18. Add 10 mM glutamate solution to the micro cuvette, mix well and record the fluorescence
 554 emission spectrum ($\lambda_{\text{ex}} = 492 \text{ nm}$ and $\lambda_{\text{em}} = 497\text{-}550 \text{ nm}$) ($F_{\text{+glu}}$).
- 555 19. To analyze the data, take the maximal emission (around 514 nm) of each measurement and
 556 calculate the fluorescence dynamic range ($(F_{\text{+glu}} - F_{\text{-glu}})/F_{\text{-glu}}$).

557 20. Repeat Steps 16-19 twice in order to generate 3 independent replicates.
558 **CRITICAL STEP:** If the fluorescence dynamic range is < 2 the fluorescence change upon glutamate
559 binding is too low for imaging in hippocampal slices. In that case, try using higher concentrations
560 of glutamate. If the fluorescence dynamic range has not improved, return to the "Selection of
561 residues close to binding pocket step" and select another mutation.

562 **Determining K_d and specificity** Timing 2 h for each ligand

563 21. Prepare 50-100 nM GEGI in 3 mL assay buffer in a 3500 μ L Hellma Quartz cuvette (QS).
564 22. Add a magnetic stir bar and place the cuvette into spectrofluorometer.
565 **CRITICAL STEP:** Make sure stir bar is moving rigorously.
566 23. Fill a 250 μ L Hamilton syringe with assay buffer with appropriate ligand: L-glutamate (10x K_d 10-
567 50 mM), L-aspartate (10x K_d 10-50 mM) or L-serine (10x K_d 10-50 mM).
568 **CRITICAL STEP:** Make sure there are no air bubbles in the syringe nor in the tubing.
569 24. Install the syringe in an Aladdin syringe pump, set the flow rate to 10 μ L/min and place the
570 tubing outlet carefully into the micro cuvette.
571 25. Simultaneously start the recording of the fluorescence emission over time (λ_{ex} = 492 nm and
572 λ_{em} = 514 nm) and the syringe pump.
573 26. To analyze the data, use time information to calculate the ligand concentration in the cuvette at
574 each given time point. Correct the fluorescence emission for dilution/photobleaching and
575 normalize it. Plot the corrected and normalized fluorescence against the ligand concentration
576 and fit with a Hill equation for specific binding (GraphPad Prism 7) to obtain affinity for
577 glutamate (K_d) and cooperativity of binding (n).
578 27. Repeat Steps 21-26 twice in order to generate at least 3 independent experiments.

579 **Measuring kinetics** Timing 5 h (4h for association, 1h for dissociation)

580 **CRITICAL:** Temperature control is essential for all kinetic measurements. Furthermore, washing the
581 instrument firmly after changing the ligand concentration is critical. To correctly analyze the data
582 baselines and maximum fluorescence intensity lines should be recorded as described below. Always
583 average at least five records ("shots") for each measurement to obtain a representative trace.

584 28. **Association (Steps 28-32):** Mix 1 μ M GEGI in assay buffer with the maximal glutamate
585 concentration in assay buffer (10x K_d , as determined in Step 27). Set the fluorescence level after
586 mixing to reach 80% detector saturation by adjusting the gain on the PMT (reference of 1 for
587 normalization). This step will prevent detector overload in future experiments.
588 29. Mix assay buffer with assay buffer and record the baseline (reference of 0 for normalization).
589 30. Mix 1 μ M GEGI in assay buffer with assay buffer. This measurement should result in a straight
590 line and shows the basal fluorescence without ligand bound.
591 **CRITICAL STEP:** Steps 28-30 need to be performed before starting any association kinetic
592 measurement of a GEGI. It ensures that the instrument is calibrated for maximum/minimum
593 fluorescence detection levels and prevents detector damage.
594 31. Glutamate dependent association kinetics: Mix 1 μ M iGluSnFR variant in assay buffer with
595 increasing glutamate concentrations in assay buffer (0.1x to 10x K_d). Record and average five
596 measurements for each glutamate concentration.

- 597 **CRITICAL STEP:** You may have to perform measurements of different time scales to have enough
598 data points for an accurate exponential fitting. Make sure you use about 10 different glutamate
599 concentrations to measure the fluorescence increase with increasing glutamate and also the
600 saturation as shown by reaching a maximum in fluorescence and on-rate.
- 601 32. To analyze the data, normalize the recorded time traces to the PMT baseline and the maximal
602 fluorescence level. Fit the time traces with mono- or biexponential decays (Kinetic studio or
603 GraphPad Prism 7). Plot the obtained observed rate constants against the glutamate
604 concentration.
- 605
- 606 33. **Dissociation (Steps 33-37):** Mix 1 μM GEGI in glutamate saturating assay buffer ($10\times K_d$, as
607 determined in Step 27) with the same buffer. Set the fluorescence level after mixing to reach
608 80% detector saturation by adjusting the gain on the PMT (reference of 1 for normalization). This
609 step will prevent detector overload in future experiments.
- 610 34. Perform step 29 to obtain the reference for 0.
- 611 35. Perform step 30 to obtain the basal fluorescence level.
- 612 **CRITICAL STEP:** Steps 34-35 need to be performed before starting any dissociation kinetic
613 measurement of a GEGI. It ensures that the instrument is calibrated for maximum/minimum
614 fluorescence detection levels and prevents detector damage.
- 615 36. Dissociation kinetics: Mix 1 μM GEGI in assay buffer with saturating glutamate concentration
616 ($10\times K_d$) with 2 mM GluBP 600n in assay buffer. Higher concentrations of GluBP 600n are not
617 advisable as precipitation might occur. Record and average five measurements.
- 618 **CRITICAL STEP:** You may have to perform measurements of different time scale to have enough
619 data points for an accurate exponential fitting.
- 620 37. To analyze the data, normalize the recorded time traces to the PMT baseline and the maximum
621 fluorescence level. Then fit the time trace with mono- or biexponential decays (Kinetic studio or
622 GraphPad Prism 7). Plot the obtained observed rate constants against the glutamate
623 concentration.

624 **Determining fluorescence dynamic range and K_d in HEK293T cells Timing 2 days (5 h hands-on**
625 **time)**

- 626 38. Seed $\sim 200,000$ cells onto 24-well glass bottom fluorescence plates in complete DMEM and let
627 them attach for 24 h in the incubator (37°C , 5% (v/v) CO_2).
- 628 39. Transfect the cells with GEGI plasmids generated by SDM of promising mutations into the
629 mammalian expression vector pCMV iGluSnFR using Lipofectamine 2000 following the
630 manufacturer's protocol.
- 631 40. Examine the cells 24 h post-transfection at 37°C with a confocal microscope (light source
632 488 nm, using GFP settings). Check for localization at the plasma membrane.
- 633 41. Glutamate titration: add stepwise glutamate to final concentrations between 0- $10\times K_d$ (as
634 determined in Step 27) and take an image of the cells before and after each addition step.
- 635 **CRITICAL STEP:** Focus drift may happen when you add glutamate. If it is the case, discard the last
636 data-point and move to a different well.
- 637 42. Define elliptical regions of interest (ROI) along cell membrane and determine the fluorescence
638 intensity (ImageJ). Normalize intensity for each individual cell and average over a total number

639 of >20 cells. Plot relative intensity versus glutamate concentration and fit data with Hill equation
640 (GraphPad Prism 7).

641 **Cloning in neuronal expression vector** **Timing 7 days (5h hands-on time)**

- 642 43. Use QuikChange XL site-directed mutagenesis kit to insert mutation of promising GEGI variants
643 into pCI syn iGluSnFR vector and confirm by DNA sequencing.
644 44. Prepare plasmid for electroporation using a plasmid DNA preparation kit (e.g. PureLink HiPure
645 Maxiprep kit from Life Technologies)

646 **Culture preparation** **Timing 15 min/brain**

- 647 45. Prepare organotypic slice cultures (rat hippocampus) as described in ³⁰.

648 **Single-cell electroporation** **Timing 10 min plus 10-20 min per slice, depending on slice quality and**
649 **number of cells to transfect**

650 46. **Preparation of plasmids and DNA (Steps 46-47):** Sterile filter an aliquot (0.5 ml) of K-gluconate-
651 based intracellular solution through a Millipore Ultrafree centrifugal unit by centrifugation at
652 16,000 *g* for several seconds in a table-top centrifuge at 4°C.

653 47. Add the GEGI plasmids to the desired concentration after removal of the filter insert. Use 40 to
654 50 ng/μL for pCI syn iGlu_f (Addgene plasmid #106121) or pCI syn iGlu_v (Addgene plasmid
655 #106122) ¹³. For different cell types and GEGIs, the final concentration may have to be
656 determined empirically (range: 1-100 ng/μL).

657 **CRITICAL STEP:** It is important that the DNA-containing solution is not passed through the
658 Millipore Ultrafree centrifugal filter unit.

659 **CRITICAL STEP:** To aid visualization of axons and boutons of transfected neurons, mix plasmid
660 encoding for red fluorescent protein (e.g. tdimer2; 20 ng/μL) with GEGI plasmid to achieve co-
661 expression.

662
663 **PAUSE POINT:** The electroporation solution containing the plasmid can be stored between
664 electroporation sessions at -20°C for up to 1 year.

665
666 48. **Electroporation (Steps 48-56):** Coat silver wires tips and ground electrodes with AgCl by bathing
667 them in a saturated Cl₃Fe solution for at least 30 min or overnight prior to first use.

668 49. Pull electroporation pipettes using a micropipette puller (e.g. PC-10, Narishige). Pull thin-walled
669 borosilicate capillaries to obtain a resistance of 10-15 MΩ when filled with the intracellular
670 solution.

671 **CRITICAL STEP:** Ensure constant pipette resistance for reproducible expression. A too high
672 pipette resistance leads to low expression, whereas a too low resistance causes extreme
673 expression levels and toxicity.

674 50. Back-fill an electroporation pipette with ~1.2 μL of plasmid mix solution (from Step 47) for each
675 slice to electroporate. Back-filled pipettes can be kept (in an upright position) for up to 2 hours
676 before use. Pipette 1 mL of transduction solution (37°C) into the microscope chamber. Transfer
677 one slice culture insert into the chamber (sterile forceps) and add transduction solution on top of

678 the slice culture for the water immersion objective. Use a sterile 60-mm dish to cover the
 679 microscope chamber to transfer to the microscope to proceed to single cell electroporation.
 680 **CRITICAL STEP:** To avoid any contamination place forceps into the hot bead sterilizer for ~ 10 sec
 681 before any handling of insert.
 682 **CRITICAL STEP:** Work on an electrophysiology microscope setup in a laminar flow box (see
 683 Equipment section) to prevent contamination.

- 684 51. Apply positive pressure to the pipette to approach a cell to electroporate. Monitor by audio
 685 output of the Axoporation 800A amplifier the tip resistance of the electroporation pipette
 686 throughout the entire procedure. The resistance should be between 10–15 MΩ.
 687 **CRITICAL STEP:** Similarly to patch-clamp recording technique, positive pressure on the
 688 electroporation pipette is maintained to keep the tip of the pipette clean while penetrating the
 689 tissue.
 690 **CRITICAL STEP:** For reproducible expression level of the plasmids between different
 691 electroporation sessions, ensure that the pipette resistance is constant.
- 692 52. Move the tip of the electroporation electrode close to a cell of interest while reducing the
 693 positive pressure.
- 694 53. Approach the cell without sealing the electrode with membranes from other cells in the tissue.
 695 Touch the plasma membrane which causes a rise in tip resistance indicated by a rise in pitch.
 696 Immediately release the pressure and wait for the resistance to increase to 25–40 MΩ. Do not
 697 apply suction and avoid the formation of a GΩ seal.
- 698 54. Apply a pulse train (e.g., voltage: –12 V, frequency: 50 Hz, pulse width: 500 μs, train duration:
 699 500 ms). The optimal settings may differ depending on the cell type to electroporate.
 700 **CRITICAL STEP:** For more reproducible expression levels of the plasmids between different cells,
 701 try to wait for the resistance to increase to a similar value before applying the pulse train.
- 702 55. Slowly retract the pipette and begin applying very light positive pressure once the pipette is
 703 retracted 2–4 μm away from the soma. Increase the positive pressure at more considerable
 704 distances from the electroporated cell in order to maintain the pipette tip clean. Using the same
 705 electrode, repeat steps 51-55 for each cell to be electroporated.
- 706 56. Cover the chamber with a 60-mm dish and transfer back to the tissue culture hood. Remove all
 707 transfection medium and return the insert to the slice culture medium. Typically, 2-4 days are
 708 needed for optimal expression levels of GEGIs in hippocampal organotypic slices. However, the
 709 optimal time for a cell to express a given plasmid before starting the experiment has to be
 710 determined empirically³⁷.

711 **Stimulating transfected neurons** **Timing 30-90 min per recording depending on slice quality,**
 712 **the number of cells expressing the electroporated plasmids and the length of the recording**

713 57. Start temperature-controlled perfusion system and place the organotypic culture in the
 714 recording chamber. Weigh down membrane patch with c-shaped gold wire.
 715 **? TROUBLESHOOTING**

- 716 58. Tune the Ti:Sapph laser to 980 nm for simultaneous excitation of tdimer2 and GEGI.
 717 **? TROUBLESHOOTING**

- 718 59. Approach a transfected CA3 neuron with the patch pipette, switching between red
719 epifluorescence and IR-Dodt contrast (CCD camera).
720 **? TROUBLESHOOTING**
- 721 60. Establish a GΩ-seal and break in to establish whole-cell configuration.
722 **CRITICAL STEP:** Stimulate an individual transfected cell to avoid stimulation of presynaptic
723 terminals close to the terminal under scrutiny. This will ensure that the GEGl transients originate
724 from the imaged terminal and are not a consequence of glutamate spillover.
- 725 61. Move the stage to center the objective on CA1. Search for red fluorescent axons using two-
726 photon excitation.
727 **? TROUBLESHOOTING**

728 **Imaging synaptic glutamate release**

- 729 62. Scan modality and signal analysis depend on the synaptic parameter under scrutiny. To localize
730 the fusion site, acquire fast frame scans followed by fitting with a Gaussian kernel (Option A). To
731 analyze the amplitude of glutamate transients, acquire spiral scans (Option B). To extract the
732 amplitude, define a region of interest in every trial and fit an exponential decay function to the
733 extracted time course.
734
- 735 **(A) Fusion site localization Timing 1 hour per recording**
- 736 i. Inject current pulses (2-3 ms, 1.5-3.5 nA) into the soma and acquire rapid frame scans of a single
737 bouton (high zoom, 16 x 16 pixels, 1 ms/line).
- 738 ii. Treat the raw images by a wavelet method to reduce photon shot noise³⁸ and improve SNR.
739 **? TROUBLESHOOTING**
- 740 iii. Upsample the images to 128 x 128 pixels (Lanczos kernel).
- 741 iv. Align the images using a Fast Fourier transform (FFT) performed on the red fluorescence signal
742 (tdimer2).
- 743 v. Define a morphology mask to define a continuous area encompassing bouton and axon (pixel
744 intensity $\geq 10\%$ to 30% maximal intensity).
- 745 vi. Calculate the relative change in GEGl fluorescence ($\Delta F/F_0$) pixel by pixel using the mean of 5
746 baseline frames as F_0 . Calculate the relative change and average the top 3% pixel values (of the
747 GEGl signal) within the bouton mask to obtain the peak amplitude.
- 748 vii. Construct a template (2-D anisotropic Gaussian kernel) from the average of 5 trials classified as
749 success. A trial is classified as success when the peak amplitude is above 2σ of the baseline
750 frames.
- 751 viii. Perform a first round of analysis where fitting the template to every single frame by adapting
752 only the amplitude and keeping the location and shape of the kernel fixed at the template values
753 to obtain a preliminary classification of 'successes' ($\Delta F/F_0 > 2\sigma$ of baseline noise) and 'failures'
754 ($\Delta F/F_0 < 2\sigma$ of baseline noise).
- 755 ix. Repeat the fitting procedure on all trials classified as successes (step viii) allowing for variable
756 location in order to localize the fusion site
757 **? TROUBLESHOOTING**
- 758 x. As a control, apply the same localization procedure to the failure trials and to the frame before
759 stimulation.

760 ? TROUBLESHOOTING

761 (B) Amplitude extraction and failure analysis **Timing 1 hour per recording**

- 762 i. Inject current pulses (2-3 ms, 1.5-3.5 nA) into soma and acquire rapid frame scans of a single
763 bouton (high zoom, 16 x 16 pixels, 1 ms/line).
- 764 ii. If a bouton shows AP-induced fluorescence increase (green channel), switch to spiral scan mode.
765 ? TROUBLESHOOTING
- 766 iii. Acquire AP-induced GEGI transients at regular intervals (10 s), using 500 or 1000 Hz sampling.
767 Image only for the duration of the GEGI transients (~20 to 80 ms) to minimize laser exposition.
- 768 iv. For amplitude extraction, linearize the spiral scans and display them as xt-plots (Fig. 5c).
- 769 v. To distinguish successful glutamate release events from failures, perform a statistical comparison
770 of fluorescence fluctuations before stimulation (ΔF baseline, $n = 64$ columns/locations) and
771 response amplitude (ΔF response, $n = 64$ columns/locations). A significant difference suggests a
772 success, lack of significance a failure trial. This classification is preliminary; the final failure
773 analysis is performed after amplitude extraction (step xi).
- 774 vi. As there may be lateral drift between individual trials, it is necessary to assign a new region of
775 interest (ROI) for each success trial. The spiral scan covering the entire bouton may hit the GEGI
776 transient once or several times per line. Sort the pixel columns (i.e., spatial positions) according
777 to the change in fluorescence (ΔF) in each column (Fig. 5d). In a given trial, only the columns
778 which display a clear change in fluorescence ($\Delta F > \frac{1}{2} \max \Delta F$) are analyzed (ROI). The threshold is
779 once adjusted according to the noise of the imaging system but should be kept constant for
780 amplitude comparisons between different experiments.
- 781 vii. In failure trials, evaluate identical columns/locations than in the last success trial.
- 782 viii. If necessary, correct traces for GEGI bleaching (see Box 1).
- 783 ix. For each bouton, extract the characteristic decay time constant (τ) by fitting a mono-exponential
784 function to the average GEGI fluorescence transient.
- 785 x. Estimate the glutamate transient amplitude for every trial by fitting an exponential function to
786 the decay of the fluorescence transient (fixed τ , amplitude as the only free parameter).
- 787 ? TROUBLESHOOTING
- 788 xi. For each trial, determine the imaging noise (σ) from the baseline of the extracted fluorescence
789 time course. Classify as 'success' trials where average $\Delta F/F_0 > 2\sigma$ above baseline imaging noise,
790 otherwise classify as 'failure'.

791 **Box 1: Bleaching of GEGI**

792 During imaging, some GEGI molecules bleach, leading to a decrease in baseline fluorescence during each
793 trial (Supplementary Figure 1). This may cause problems when fitting an exponential function to the
794 decay of the glutamate response, since at least two time constants have to be taken into account. To
795 correct individual trials from one bouton for bleaching, fit an exponential decay function to the average
796 of several 'failure' trials. Subtract this function from each trial (failures and successes; step 63B viii).
797 Between trials, fluorescence partially recovers, indicating lateral diffusion of GEGI molecules in the
798 axonal membrane. Some loss of GEGI fluorescence (20-40%) during the course of the experiment can be

799 tolerated since it does not affect the glutamate-induced relative change in fluorescence ($\Delta F/F_0$,
800 Supplementary Figure 1). We found that manual refocusing between trials can lead to substantial
801 bleaching of the indicator. This can be minimized by automated refocusing between trials.

802 **Troubleshooting**

803 Step 57: Slices are contaminated. See ³⁰ for proper slice culture handling.

804 Step 58: No cells express the construct. Ensure that the constructs are incorporated into the target cells
805 by adding a fluorescent dye such as Alexa Fluor 594 to the DNA mix (Step 47). After applying the pulse
806 train to the target neuron (Step 54), take a fluorescence image (e.g., Leica Z6 APO) to ensure that the
807 DNA solution and fluorescent dye were successfully electroporated. For more details for the
808 electroporation procedure refer to ³⁷.

809 Step 59: Cells are dying after transfection with the constructs. Lower the expression of the GEG1, ensure
810 that the pipette resistance (Step 49) is not lower than 10-15 M Ω in the bath before electroporation,
811 and/or reduce expression time. A large pipette tip diameter (low resistance) can lead to overexpression
812 of the GEG1 and cell toxicity. Cells should be imaged 2-4 days after electroporation, as longer expression
813 of GEG1s can affect cell health.

814 **CAUTION:** Very strong promoters (CMV) should not be used for physiological experiments in neurons.

815 Step 61: Slice is drifting, focus is not stable. Lower the perfusion rate. Check that the temperatures of the
816 perfusion solution and of the imaging chamber of the microscope are stable to avoid thermal expansion
817 during the experiment.

818 Step 62A (ii): The responses are very weak and barely above noise. Wait longer after electroporation for
819 a higher expression level. If the expression levels are too low, the GEG1 signal from a single vesicle may
820 be below the detection limit. The detection limit is determined by the noise level of the optical recording
821 setup. Minimize background fluorescence, which can be caused by leaking room light, stray pump laser
822 photons (green), or excessive dark counts in aging PMTs. Condenser detection is sensitive to the
823 refractive index of the immersion oil and correct (Köhler) position.

824 Step 62A (ix): The localization seems inaccurate. Calibrate the optical and mechanical performance of
825 your system using fluorescent microbeads. Imaging of microbeads (0.17 μm diameter) positioned next to
826 a fluorescent presynaptic terminal allows quantifying the accuracy of the response localization
827 procedure.

828 Step 62A (x): In cases where the positions of apparent 'failures' clusters in a second area of the bouton,
829 exclude the bouton from further analysis as it might be a multi-synapse bouton.

830
831 Step 62B (ii): The success rate in finding a bouton releasing glutamate is very low. This can be due to low
832 release probability. Check $[\text{Ca}^{2+}]$ of the ACSF.

833 Step 62B (x): In some trials, the baseline fluorescence may show large fluctuations caused by green
834 fluorescent vesicles passing through the axon. Remove these trials from further analysis.

835 **Timing**

836	Steps 1-4	Generation of GEGIs	7 days (5 h hands-on-time)
837	Steps 5-15	Expression and purification of new GEGIs	3 days (10 h hands-on-time)
838	Steps 16-20	Dynamic range determination	1 h
839	Steps 21-27	K_d determination	2h/ligand
840	Steps 28-32	Association kinetics	4 h/variant
841	Steps 33-37	Dissociation kinetics	1 h/variant
842	Steps 38-42	Determination of dynamic range and K_d in cells	2 days (5 h hands-on time)
843	Steps 43-44	Subcloning into neuronal expression vector	7 days (5 h hands-on time)
844	Step 45	Culture preparation	15 min/brain
845	Steps 46-47	Preparation of plasmids and DNA	10 min
846	Steps 48-56	Single-cell electroporation	10-20 min/slice
847	Steps 57-61	Stimulating transfected neurons	30-90 min/recording
848	Steps 62A (i-x)	Fusion site localization	1 h/recording
849	Steps 62B (i-xi)	Amplitude extraction and failure analysis	1h/recording

850 **Anticipated results**

851 **Assessing the properties of neighboring boutons**

852 Once a responding bouton is identified, several neighboring boutons along the same axon can be imaged
853 sequentially. Neighboring boutons frequently have similar release probabilities and response amplitudes
854 (Fig. 6a). In rare cases, however, we found dramatic differences in response amplitude between
855 neighboring boutons (Fig. 6b). To test whether boutons on the same axon are functionally similar, we
856 generated random pairs by drawing from our entire set of characterized boutons. The differences
857 between randomly selected boutons are normally distributed (black bars in Fig. 6d). The actual
858 difference between neighboring boutons (red line in Fig. 6d) is at the low end of the distribution,
859 indicating that neighboring boutons tended to have similar release probabilities. A similar result,
860 however non-significant, was found when response amplitudes were analyzed (Fig. 6e and f).

861 **Application of fast GEGIs**

862 While iGluSnFR has an excellent SNR, it is too slow to resolve vesicle fusion events during high-frequency
863 transmission³⁹. Recently developed ultrafast GEGIs, iGlu_u and iGlu_f¹³ resolve individual responses during
864 100 Hz trains, albeit with slightly lower SNR as shorter transients correspond to fewer photons collected
865 (Fig. 7a). For these experiments, scan speed was increased to 1 kHz, and a high Ca²⁺ solution was used to
866 increase release probability. Under these conditions, individual boutons typically had a release
867 probability of 1 on the first AP, which rapidly dropped to ~0.2 towards the end of the 100 Hz train. After
868 a brief recovery period (0.5 s), most boutons could restore their initial high release probability (Fig. 7b
869 and c). Interestingly, the depression also affected the amplitude of individual successes, suggesting a

870 switch from multivesicular release (MVR) to univesicular release during high-frequency activity^{1,40}.
871 Alternatively, a switch from full fusion to partial fusion of synaptic vesicles⁴¹ could explain this
872 observation. Responses from an iGluSnFR-expressing bouton during high-frequency stimulation are
873 shown for comparison (blue traces, Fig. 7a). Summation of 100 Hz release events drives this slow GEGI
874 towards saturation, making it impossible to disentangle single-pulse responses by deconvolution. As
875 saline with high calcium concentration (4 mM) was used in these experiments, the prevalence of MVR
876 under more physiological conditions remains to be investigated. In this context, an important advantage
877 of GEGI measurements compared to GECIs⁴² is their independence from extracellular $[Ca^{2+}]_e$, allowing to
878 investigate the impact of changes in $[Ca^{2+}]_e$ on presynaptic function⁴³. In summary, ultrafast GEGIs allow
879 direct visualization of short-term plasticity at individual synapses and may help unraveling the underlying
880 biophysical mechanisms.

881 **Data availability**

882 The data that support the findings of this study are available from the corresponding author (Email:
883 thomas.oertner@zmnh.uni-hamburg.de) on request.

884 **Acknowledgements**

885 The authors thank Iris Ohmert and Sabine Graf for the preparation of organotypic cultures and excellent
886 technical assistance. This study was supported by the German Research Foundation through Research
887 Unit FOR 2419 P4 (TGO) and P7 (SW), Priority Programs SPP 1665 (TGO) and SPP 1926 (SW),
888 Collaborative Research Center SFB 936 B7 (TGO), and BBSRC grants BB/M02556X/1 (KT) and
889 BB/S003894 (KT).

890 **Author contributions**

891 C.D.D., J.S.W, K.T., and T.G.O. designed the experiments and prepared the manuscript. C.D.D. performed
892 synaptic imaging experiments. N.H., S.K., C.C. and M.G. created and characterized novel iGluSnFR
893 variants, C.S. wrote software to acquire and analyze GEGI data.

894 **Competing interest statement**

895 The authors declare no competing interests.

896 **References**

- 897 1. Pulido, C. & Marty, A. Quantal Fluctuations in Central Mammalian Synapses: Functional Role of
898 Vesicular Docking Sites. *Physiol. Rev.* **97**, 1403–1430 (2017).
- 899 2. Choquet, D. & Triller, A. The Dynamic Synapse. *Neuron* **80**, 691–703 (2013).
- 900 3. Namiki, S., Sakamoto, H., Iinuma, S., Iino, M. & Hirose, K. Optical glutamate sensor for
901 spatiotemporal analysis of synaptic transmission. *Eur. J. Neurosci.* **25**, 2249–59 (2007).
- 902 4. Okubo, Y. *et al.* Imaging extrasynaptic glutamate dynamics in the brain. *Proc. Natl. Acad. Sci. U. S.*

- 903 A. **107**, 6526–31 (2010).
- 904 5. Brun, M. A. *et al.* A semisynthetic fluorescent sensor protein for glutamate. *J. Am. Chem. Soc.* **134**,
905 7676–7678 (2012).
- 906 6. Okumoto, S. *et al.* Detection of glutamate release from neurons by genetically encoded surface-
907 displayed FRET nanosensors. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 8740–5 (2005).
- 908 7. Tsien, R. Y. Building and breeding molecules to spy on cells and tumors. in *FEBS Letters* **579**, 927–
909 932 (2005).
- 910 8. Hires, S. A., Zhu, Y. & Tsien, R. Y. Optical measurement of synaptic glutamate spillover and
911 reuptake by linker optimized glutamate-sensitive fluorescent reporters. *Proc. Natl. Acad. Sci. U. S.*
912 *A.* **105**, 4411–4416 (2008).
- 913 9. Marvin, J. S. *et al.* An optimized fluorescent probe for visualizing glutamate neurotransmission.
914 *Nat. Methods* **10**, 162–170 (2013).
- 915 10. Borghuis, B. G., Looger, L. L., Tomita, S. & Demb, J. B. Kainate Receptors Mediate Signaling in Both
916 Transient and Sustained OFF Bipolar Cell Pathways in Mouse Retina. *J. Neurosci.* **34**, 6128–6139
917 (2014).
- 918 11. O’Herron, P. *et al.* Neural correlates of single-vessel haemodynamic responses in vivo. *Nature*
919 **534**, 378–382 (2016).
- 920 12. Brunert, D., Tsuno, Y., Rothermel, M., Shipley, M. T. & Wachowiak, M. Cell-Type-Specific
921 Modulation of Sensory Responses in Olfactory Bulb Circuits by Serotonergic Projections from the
922 Raphe Nuclei. *J. Neurosci.* **36**, 6820–6835 (2016).
- 923 13. Helassa, N. *et al.* Ultrafast glutamate sensors resolve high-frequency release at Schaffer collateral
924 synapses. *Proc. Natl. Acad. Sci. U. S. A.* **115**, 5594–5599 (2018).
- 925 14. Wu, J. *et al.* Genetically Encoded Glutamate Indicators with Altered Color and Topology. *ACS*
926 *Chem Biol.* **13**, 1832–1837 (2018).
- 927 15. Marvin, J. S. *et al.* Stability, affinity, and chromatic variants of the glutamate sensor iGluSnFR. *Nat.*
928 *Methods* **15**, 936–939 (2018).
- 929 16. Miesenbock, G., De Angelis, D. A. & Rothman, J. E. Visualizing secretion and synaptic transmission
930 with pH-sensitive green fluorescent proteins. *Nature* **394**, 192–195 (1998).
- 931 17. Granseth, B., Odermatt, B., Royle, S. J. & Lagnado, L. Clathrin-mediated endocytosis is the
932 dominant mechanism of vesicle retrieval at hippocampal synapses. *Neuron* **51**, 773–786 (2006).
- 933 18. Fernández-Alfonso, T., Kwan, R. & Ryan, T. A. Synaptic Vesicles Interchange Their Membrane
934 Proteins with a Large Surface Reservoir during Recycling. *Neuron* **51**, 179–186 (2006).
- 935 19. Voglmaier, S. M. *et al.* Distinct Endocytic Pathways Control the Rate and Extent of Synaptic Vesicle
936 Protein Recycling. *Neuron* **51**, 71–84 (2006).
- 937 20. Li, H. Concurrent imaging of synaptic vesicle recycling and calcium dynamics. *Front. Mol. Neurosci.*
938 **4**, 1–10 (2011).

- 939 21. Li, Y. & Tsien, R. W. pHTomato, a red, genetically encoded indicator that enables multiplex
940 interrogation of synaptic activity. *Nat. Neurosci.* **15**, 1047–53 (2012).
- 941 22. Rose, T., Schoenenberger, P., Jezek, K. & Oertner, T. G. Developmental refinement of vesicle
942 cycling at Schaffer collateral synapses. *Neuron* **77**, 1109–21 (2013).
- 943 23. Balaji, J. & Ryan, T. A. Single-vesicle imaging reveals that synaptic vesicle exocytosis and
944 endocytosis are coupled by a single stochastic mode. *Proc. Natl. Acad. Sci.* **104**, 20576–20581
945 (2007).
- 946 24. Gandhi, S. P. & Stevens, C. F. Three modes of synaptic vesicular recycling revealed by single-
947 vesicle imaging. *Nature* **423**, 607–13 (2003).
- 948 25. Zhu, Y., Xu, J. & Heinemann, S. F. Synaptic vesicle exocytosis-endocytosis at central synapses.
949 *Commun. Integr. Biol.* **2**, 418–419 (2009).
- 950 26. Maschi, D. & Klyachko, V. A. Spatiotemporal Regulation of Synaptic Vesicle Fusion Sites in Central
951 Synapses. *Neuron* **94**, 65–73.e3 (2017).
- 952 27. Betz, W. J. & Bewick, G. S. Optical analysis of synaptic vesicle recycling at the frog neuromuscular
953 junction. *Science* **255**, 200–3 (1992).
- 954 28. Laviv, T. *et al.* Simultaneous dual-color fluorescence lifetime imaging with novel red-shifted
955 fluorescent proteins. *Nat. Methods* **13**, 989–992 (2016).
- 956 29. Campbell, R. E. *et al.* A monomeric red fluorescent protein. *Proc Natl Acad Sci U S A* **99**, 7877–
957 7882 (2002).
- 958 30. Gee, C. E., Ohmert, I., Wiegert, J. S. & Oertner, T. G. Preparation of Slice Cultures from Rodent
959 Hippocampus. *Cold Spring Harb. Protoc.* **2017**, pdb.prot094888 (2017).
- 960 31. Pologruto, T. A., Sabatini, B. L. & Svoboda, K. ScanImage: Flexible software for operating laser
961 scanning microscopes. *Biomed Eng Online* **2**, 13 (2003).
- 962 32. Suter, B. A. *et al.* Ephus: multipurpose data acquisition software for neuroscience experiments.
963 *Front. Neural Circuits* **4**, 1–12 (2010).
- 964 33. Negrean, A. & Mansvelder, H. D. Optimal lens design and use in laser-scanning microscopy.
965 *Biomed. Opt. Express* **5**, 1588–609 (2014).
- 966 34. Jensen, T. P., Zheng, K., Tyurikova, O., Reynolds, J. P. & Rusakov, D. A. Monitoring single-synapse
967 glutamate release and presynaptic calcium concentration in organised brain tissue. *Cell Calcium*
968 **64**, 102–108 (2017).
- 969 35. Hires, S. A., Zhu, Y. & Tsien, R. Y. Optical measurement of synaptic glutamate spillover and
970 reuptake by linker optimized glutamate-sensitive fluorescent reporters. *Proc Natl Acad Sci U S A*
971 **105**, 4411–4416 (2008).
- 972 36. de Lorimier, R. M. *et al.* Construction of a fluorescent biosensor family. *Protein Sci.* **11**, 2655–75
973 (2002).
- 974 37. Wiegert, J. S., Gee, C. E. & Oertner, T. G. Single-cell electroporation of neurons. *Cold Spring Harb.*
975 *Protoc.* **2017**, 135–138 (2017).

- 976 38. Luisier, F., Vonesch, C., Blu, T. & Unser, M. Fast interscale wavelet denoising of Poisson-corrupted
977 images. *Signal Processing* **90**, 415–427 (2010).
- 978 39. Taschenberger, H., Woehler, A. & Neher, E. Superpriming of synaptic vesicles as a common basis
979 for intersynapse variability and modulation of synaptic strength. *Proc. Natl. Acad. Sci.* **113**,
980 E4548–E4557 (2016).
- 981 40. Oertner, T. G., Sabatini, B. L., Nimchinsky, E. A. & Svoboda, K. Facilitation at single synapses
982 probed with optical quantal analysis. *Nat. Neurosci.* **5**, 657–64 (2002).
- 983 41. Grabner, C. P. & Moser, T. Individual synaptic vesicles mediate stimulated exocytosis from
984 cochlear inner hair cells. *Proc. Natl. Acad. Sci.* **115**, 12811–12816 (2018).
- 985 42. Helassa, N., Podor, B., Fine, A. & Török, K. Design and mechanistic insight into ultrafast calcium
986 indicators for monitoring intracellular calcium dynamics. *Sci. Rep.* **6**, 38276 (2016).
- 987 43. Zucker, R. S. & Regehr, W. G. Short-Term Synaptic Plasticity. *Annu. Rev. Physiol.* **64**, 355–405
988 (2002).

989 **Figure legends**

990 **Fig 1: Overview of the protocol workflow for the development of glutamate sensors and 2-**
991 **photon imaging of glutamate transients in individual synapses.**

992 **Fig 2: Characterization of GEGIs.**

993 (a) Left: Setup for affinity and selectivity determination. GEGI in assay buffer is placed into a fluorescence
994 cuvette with a magnetic stirrer and placed inside the sample chamber of the fluorescence spectrometer
995 (Fluorolog3, Horiba Scientific). With an Aladdin pump, the ligand (Glu, Asp, Ser) is continuously added to
996 the cuvette while the fluorescence is recorded ($\lambda_{ex} = 492$ nm, $\lambda_{em} = 514$ nm). Right: Examples of affinity
997 curves of a GEGI for glutamate (black squares) and aspartate (black circles). The fluorescence emission is
998 corrected for dilution and bleaching and plotted against the glutamate concentration in the chamber.
999 The data is then fitted with a Hill equation (green and orange traces for glutamate and aspartate,
1000 respectively). (b) Left: Setup for stopped-flow kinetic measurement. The solutions are rapidly mixed in
1001 the mixing chamber and then pushed into the optical cell where the fluorescence is excited at 492 nm
1002 and emission is detected by a PMT with a cut-off filter (>530 nm). For association the GEGI in assay
1003 buffer without glutamate is loaded into the drive syringe B and mixed with assay buffer containing
1004 increasing concentrations of glutamate filled in drive syringe A. For dissociation the GEGI in assay buffer
1005 with saturating glutamate concentration is loaded into the drive syringe B and mixed with GluBP 600n in
1006 assay buffer filled into drive syringe A. For both measurements the PMT zero level is determined by
1007 mixing assay buffer with assay buffer and the intrinsic fluorescence of the GEGI is recorded by mixing the
1008 GEGI in assay buffer with assay buffer (both without Glu). Right: Examples for recorded time traces. Top:
1009 Fluorescence increase observed when GEGIs are mixed with increasing glutamate concentration.
1010 Bottom: Decrease in fluorescence when glutamate is retained from GEGI by GluBP 600n. The raw data
1011 are fitted with monoexponential decays (dark green line).

1012 **Fig 3: iGluSnFR expression in CA3 pyramidal cells in organotypic slice culture of rat**
1013 **hippocampus.**

1014 (a) Co-expression of two plasmids in individual CA3 pyramidal cells in organotypic slice culture. The red
1015 fluorescent protein tdimer2 labels the axoplasm while the membrane-anchored iGluSnFR is exposed to
1016 the extracellular space. (b) Transmitted light image (dark field) of a transfected organotypic culture
1017 merged with a wide-field fluorescence image showing three transfected CA3 neurons. The area for
1018 synaptic imaging is indicated (red dotted box). Scale bar represents 500 μm . (c) Two-photon image stack
1019 (maximum intensity projection) of CA3 axons in CA1 *stratum radiatum* (cells not identical to panel b).
1020 Scale bar represents 10 μm . Image from ¹³. (d) Maximum intensity projection of two-photon images of
1021 CA3 pyramidal neuron expressing iGlu_v 4 days after electroporation (fluorescence intensity is shown as
1022 inverted gray values). iGlu_v shown here and other GEGIs had their fluorescence mainly localized to the
1023 plasma membrane over the entire cell. The scale bar represents 50 μm (left image) and 5 μm (right
1024 image). (e) Action potentials are elicited in a transfected neuron by somatic current injections and
1025 glutamate release is simultaneously optically recorded (GEGI fluorescence) from a single Schaffer
1026 collateral bouton in CA1, showing a broad distribution of amplitudes and occasional failures. Images
1027 were acquired at 500 Hz at 34°C. Individual trials are classified as successes if the peak amplitude of the
1028 GEGI transient is $>2\sigma$ (green traces) and as failures when the peak amplitude is $<2\sigma$ (gray traces). Note
1029 propagation delay between presynaptic APs and glutamate release events at distal bouton.

1030 **Fig 4: Localization of fluorescence transients in low and high $[\text{Ca}^{2+}]_o$.**

1031 (a) Morphology of individual boutons. Red fluorescence was upsampled (16 x 16 pixels to 128 x 128
1032 pixels), aligned and averaged over all trials. Scale bars represent 0.5 μm . (b) Average response of
1033 iGluSnFR superimposed with bouton outline (black line) from red channel (morphology). The bouton
1034 outline was generated by thresholding the red channel followed by smoothing. (c) Two-dimensional
1035 Gaussian fit to average response. On average, the full width at half maximum (FWHM) was 763 ± 29 nm
1036 ($n = 12$; 5 boutons shown here) (d) Plotting the center position of 2D Gaussian fits to individual trials.
1037 Fusion appears to be localized to a small region on the bouton (active zone). Amplitude ($\Delta F/F_0$) of
1038 individual trials is color-coded. Scale bars represent 0.5 μm . (e) Increasing the extracellular Ca^{2+}
1039 concentration increased the amplitude of individual responses, but did not lead to release events outside
1040 the active zone. (f) Fitting responses classified as failures ($< 2\sigma$ of baseline noise) did not reveal any
1041 clustering, indicating that there was indeed no localized signal in these trials (true negatives). (g) Fitting
1042 frames before stimulation (green baseline fluorescence) did also not result in clustering.

1043 **Fig. 5: Signal extraction of GEGI transients from a single Schaffer collateral bouton in CA1.**

1044 (a) The spatial extent of iGluSnFR fluorescence transients was 760 nm, on average (FWHM, short axis of
1045 Gaussian fits). No deconvolution was applied. (b) Sampling the surface of the bouton by traditional raster
1046 scanning requires extreme acceleration of the scan mirrors at the turning points, leading to large
1047 positional errors. Spiral scans avoid sharp direction changes (no flyback) and can, therefore, sample the
1048 entire bouton surface in 1 or 2 ms. Due to the elongated PSF (1.8 μm in the axial direction), upper and
1049 lower surface of a bouton are sampled simultaneously. (c) Plotting the unfolded spiral scan lines vs. time
1050 (single trial). Raw fluorescence intensity is coded in pseudocolors. At $t = 58$ ms, a glutamate release
1051 event from an individual presynaptic terminal occurred and was sampled twice during every spiral scan.
1052 (d) Only columns with $\Delta F > \frac{1}{2} \max(\Delta F)$ were analyzed (ROI, region of interest). Green trace: Extracted

1053 fluorescence transient (before bleach correction). (e) *Upper panel*: Average of 10 trials (single APs) to
1054 analyze lateral spread of signal from t=0 to t=18 ms. *Lower panel*: Decay of fluorescence transient (5 scan
1055 lines plotted = 18 ms). Note the lack of lateral spread of the signal due to slow diffusion of membrane-
1056 anchored GEGl. (f) iGluSnFR response amplitude (green markers) of a single bouton stimulated with
1057 single APs every 10 s. Note that response amplitudes were constant over time. A time window before
1058 stimulation was analyzed to estimate imaging noise (gray markers). The histogram of response
1059 amplitudes shows separation between failures of glutamate release (overlap with the baseline
1060 histogram) and successes.

1061 **Fig. 6: Release statistics of neighboring boutons on the same axon.**

1062 (a) Glutamate transients (green dots) and baseline fluorescence (grey dots) of two neighboring boutons
1063 measured in ACSF containing 2 mM Ca^{2+} and 1 mM Mg^{2+} located on the same axon (left panels) and their
1064 corresponding histogram counts (right panels). (b) Glutamate transients (blue dots) and baseline
1065 fluorescence (grey dots) of two neighboring boutons located on the same axon (left panels) and their
1066 corresponding histograms (right panels) measured in ACSF containing 2 mM Ca^{2+} and 1 mM Mg^{2+} and
1067 their corresponding histogram counts (right panels). (c) Synaptic release probability (p_r) (calculated out
1068 of ~ 100 trials) of individual boutons (B1) and their neighboring bouton on the same axon (B2); n=10. The
1069 pair of neighboring boutons from (a) and (b) are shown in green and blue, respectively. (d) Histogram of
1070 $\Delta p_r = |p_r, \text{BX} - p_r, \text{BY}|$. BX and BY are randomly paired from the dataset in (c). $|\Delta p_r, \text{B2} - \Delta p_r, \text{B1}|$ (red vertical
1071 line) is significantly more similar than mean Δp_r of two boutons paired randomly from the same dataset;
1072 (p-value: 0.0148). (e) Amplitude of the iGluSnFR signal given a success of a bouton B1 and its neighbor on
1073 the same axon (B2); n=10. The pair of neighboring boutons from (a) and (b) are shown in green and blue,
1074 respectively. (f) Histogram count of the difference between the average $\Delta F/F_0$ of successes only of two
1075 random neighboring boutons. The difference of the average $\Delta F/F_0$ of successes from two neighboring
1076 boutons (red vertical line) is not significantly more similar than the randomly connected pairs of boutons.



1077 **Fig. 7: Resolving high-frequency transmission with ultrafast GEGl, iGlu_u.**






1078 (a) The presynaptic neuron was driven to spike at 100 Hz (10 APs). After a pause of 0.5 s, one more AP
1079 was triggered to quantify recovery from depression. iGluSnFR signals (blue) or iGlu_u signals (green) were
1080 recorded at single Schaffer collateral boutons (only during the 100 Hz train) in *stratum radiatum*.
1081 Recordings were performed in 4 mM Ca^{2+} and 1 mM Mg^{2+} to ensure very high release probability. Note
1082 summation and saturation of iGluSnFR (but not iGlu_u) during the high-frequency train. (b) iGlu_u responses
1083 to the 1st AP of the 100 Hz train, to the 9th AP of the train, and to the recovery pulse. To minimize
1084 bleaching, the bouton was only imaged (spiral scans) during pulses 1, 9 and 11. Note frequent failures in
1085 response to pulse 9. (c) Extracted single-trial amplitudes reveal strong depression and full recovery of
1086 this bouton. Failures of glutamate release can be seen in response to pulse 9. Note the large amplitude
1087 of initial responses compared to depressed responses. Plots were generated with violinplot.m (GitHub,
1088 ©Bastian Bechtold).





1089

1090 **SUPPLEMENTARY MATERIAL**

1091 - **Supplementary Figure 1**

a**Flowchart of sensor development****b****Flowchart of fast imaging in hippocampal slices**





d

